NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Last Close
Jul 01 09:36AM ET
0.7295
Dollar change
+0.0082
Percentage change
1.14
%
Index- P/E- EPS (ttm)-10.59 Insider Own8.14% Shs Outstand7.44M Perf Week-0.21%
Market Cap5.43M Forward P/E- EPS next Y- Insider Trans-0.16% Shs Float6.84M Perf Month-24.79%
Enterprise Value0.36M PEG- EPS next Q- Inst Own6.43% Short Float2.79% Perf Quarter-43.88%
Income-13.61M P/S- EPS this Y- Inst Trans0.83% Short Ratio0.03 Perf Half Y-73.85%
Sales0.00M P/B0.15 EPS next Y- ROA-73.42% Short Interest0.19M Perf YTD-76.84%
Book/sh4.80 P/C1.02 EPS next 5Y- ROE-82.81% 52W High7.50 -90.27% Perf Year-86.13%
Cash/sh0.72 P/FCF- EPS past 3/5Y-88.65% -282.28% ROIC-104.84% 52W Low0.70 3.75% Perf 3Y-96.46%
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin- Volatility5.69% 6.26% Perf 5Y-
Dividend TTM- EV/Sales- EPS Y/Y TTM25.93% Oper. Margin- ATR (14)0.08 Perf 10Y-
Dividend Ex-Date- Quick Ratio3.84 Sales Y/Y TTM-100.00% Profit Margin- RSI (14)35.12 Recom1.00
Dividend Gr. 3/5Y- - Current Ratio3.84 EPS Q/Q56.49% SMA20-9.14% Beta0.25 Target Price40.00
Payout- Debt/Eq0.02 Sales Q/Q- SMA50-29.49% Rel Volume0.04 Prev Close0.72
Employees4 LT Debt/Eq0.00 Earnings- SMA200-68.42% Avg Volume6.18M Price0.73
IPOSep 15, 2021 Option/ShortNo / Yes EPS/Sales Surpr.-5.88% -33.33% Trades Volume16,931 Change1.14%
Jun-11-25 07:02AM
Jun-02-25 08:02AM
May-20-25 07:01AM
May-14-25 07:02AM
May-07-25 05:00PM
11:35AM Loading…
11:35AM
May-06-25 11:10AM
07:03AM
Apr-29-25 07:02AM
Apr-24-25 07:02AM
Apr-10-25 07:02AM
Mar-24-25 06:59AM
Feb-05-25 06:59AM
Jan-14-25 08:02AM
Nov-20-24 07:02AM
06:44PM Loading…
Sep-26-24 06:44PM
07:02AM
Sep-09-24 08:01AM
Sep-03-24 08:02AM
Aug-28-24 09:11AM
Jun-25-24 12:52PM
Jun-13-24 06:59AM
May-28-24 06:59AM
May-15-24 09:53AM
Apr-29-24 07:59AM
Apr-24-24 07:59AM
Apr-15-24 11:00AM
Feb-13-24 07:59AM
Jan-08-24 07:59AM
Jan-02-24 08:35AM
05:00PM Loading…
Dec-28-23 05:00PM
Dec-19-23 05:19PM
Dec-13-23 09:03AM
Dec-11-23 11:18AM
08:01AM
Nov-29-23 04:27PM
07:59AM
Nov-09-23 07:59AM
Sep-14-23 08:30AM
Sep-07-23 04:14PM
Aug-01-23 07:59AM
Jul-31-23 06:00AM
Jul-20-23 08:43AM
08:40AM
Jul-13-23 09:14AM
Jun-30-23 09:28AM
Jun-29-23 02:50PM
08:29AM
Jun-06-23 04:30PM
Jun-05-23 09:00AM
Jun-01-23 07:57AM
May-14-23 08:13AM
May-03-23 08:26AM
Mar-02-23 08:00AM
Feb-23-23 08:00AM
Feb-16-23 07:30AM
Jan-18-23 08:00AM
Dec-14-22 05:18PM
Dec-12-22 07:00AM
Dec-07-22 04:00PM
Dec-06-22 08:00AM
Nov-28-22 07:05PM
Nov-22-22 04:00PM
Oct-27-22 09:50AM
Oct-17-22 08:00AM
Oct-14-22 09:48AM
Oct-13-22 04:00PM
Oct-12-22 08:00AM
07:31AM
Oct-10-22 09:39AM
Oct-03-22 06:03PM
09:09AM
Sep-28-22 09:00AM
Sep-20-22 08:00AM
Sep-15-22 08:00AM
Sep-12-22 11:53AM
Sep-09-22 10:32AM
Sep-06-22 09:30AM
Aug-24-22 08:00AM
Aug-18-22 08:00AM
Aug-11-22 08:00AM
07:30AM
Aug-05-22 09:00AM
Aug-02-22 07:00AM
Jul-14-22 08:00AM
Jun-23-22 09:00AM
08:00AM
Jun-22-22 08:00AM
07:30AM
Apr-14-22 04:15PM
Apr-05-22 03:57PM
Mar-30-22 04:15PM
Mar-08-22 08:00AM
07:30AM
Feb-24-22 08:00AM
Feb-09-22 08:00AM
Feb-03-22 08:00AM
Jan-26-22 08:00AM
Dec-23-21 11:35AM
07:36AM
Pasithea Therapeutics Corp. is a biotechnology company focused on the research and discovery of new and treatments for psychiatric and neurological disorders. The company was founded by Yassine Bendiabdallah and Lawrence J. Steinman on May 12, 2020 and is headquartered in Miami Beach, FL.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Tiago Reis MarquesOfficer, DirectorMay 12 '25Proposed Sale0.83960798May 14 09:55 PM
Marques TiagoChief Executive OfficerMay 12 '25Sale0.8296079240,001May 14 09:55 PM
Last Close
Jul 01 09:34AM ET
0.9449
Dollar change
+0.0167
Percentage change
1.80
%
ATNF 180 Life Sciences Corp daily Stock Chart
Index- P/E- EPS (ttm)-5.38 Insider Own47.75% Shs Outstand5.19M Perf Week8.24%
Market Cap5.73M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float2.91M Perf Month-7.81%
Enterprise Value2.16M PEG- EPS next Q- Inst Own0.51% Short Float1.32% Perf Quarter-3.59%
Income-15.48M P/S- EPS this Y- Inst Trans-8.39% Short Ratio0.29 Perf Half Y-66.61%
Sales0.00M P/B0.64 EPS next Y- ROA-98.96% Short Interest0.04M Perf YTD-48.08%
Book/sh1.49 P/C1.54 EPS next 5Y- ROE-221.23% 52W High17.75 -94.68% Perf Year-37.84%
Cash/sh0.61 P/FCF- EPS past 3/5Y60.23% 55.37% ROIC-200.79% 52W Low0.66 43.65% Perf 3Y-99.73%
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin- Volatility12.67% 8.11% Perf 5Y-99.98%
Dividend TTM- EV/Sales- EPS Y/Y TTM87.16% Oper. Margin- ATR (14)0.09 Perf 10Y-
Dividend Ex-Date- Quick Ratio1.02 Sales Y/Y TTM- Profit Margin- RSI (14)48.50 Recom1.00
Dividend Gr. 3/5Y- - Current Ratio1.02 EPS Q/Q60.05% SMA20-1.03% Beta0.24 Target Price1520.00
Payout- Debt/Eq0.02 Sales Q/Q- SMA50-6.36% Rel Volume0.53 Prev Close0.93
Employees3 LT Debt/Eq0.00 Earnings- SMA200-43.16% Avg Volume134.34K Price0.94
IPOJun 27, 2017 Option/ShortNo / Yes EPS/Sales Surpr.84.62% - Trades Volume4,582 Change1.80%
Date Action Analyst Rating Change Price Target Change
Sep-15-21Initiated Maxim Group Buy $11
Today 07:30AM
May-01-25 09:30AM
Apr-30-25 08:30AM
Dec-27-24 09:00AM
Dec-12-24 08:00AM
08:00AM Loading…
Dec-04-24 08:00AM
Oct-31-24 08:00AM
Oct-29-24 08:00AM
Oct-25-24 09:00AM
Oct-17-24 10:52AM
Oct-16-24 08:00AM
Oct-09-24 08:30AM
Oct-03-24 08:30AM
Sep-12-24 04:15PM
Jul-30-24 08:00AM
08:00AM Loading…
Jul-23-24 08:00AM
Jul-02-24 08:30AM
May-16-24 11:53AM
Mar-14-24 08:30AM
Feb-26-24 07:00AM
Dec-04-23 09:00AM
Nov-28-23 09:00AM
Aug-14-23 04:29PM
Aug-10-23 08:46AM
Aug-07-23 09:00AM
Aug-03-23 08:00AM
Jul-31-23 08:00AM
Apr-10-23 04:30PM
Apr-05-23 01:00PM
Feb-27-23 08:30AM
07:30AM Loading…
Feb-23-23 07:30AM
Feb-22-23 04:30PM
Jan-25-23 08:45AM
Jan-17-23 08:00AM
Jan-05-23 08:30AM
Jan-04-23 08:30AM
Dec-29-22 08:30AM
Dec-23-22 08:00AM
Dec-20-22 02:11PM
Dec-16-22 09:00AM
Nov-30-22 05:00PM
Nov-21-22 08:30AM
Nov-15-22 12:37PM
08:00AM
Sep-26-22 08:30AM
Aug-22-22 08:30AM
Jul-27-22 08:30AM
Jul-21-22 08:00AM
Jul-18-22 08:30AM
Jun-22-22 04:05PM
Jun-14-22 04:15PM
May-31-22 08:30AM
May-02-22 08:00AM
Apr-29-22 06:32PM
Feb-17-22 08:30AM
Jan-31-22 08:00AM
Dec-28-21 11:00AM
Dec-15-21 08:15AM
Dec-12-21 06:06AM
Dec-10-21 05:15PM
Dec-06-21 08:15AM
Dec-01-21 02:45PM
02:26PM
Nov-22-21 08:30AM
Nov-18-21 08:15AM
Nov-03-21 12:06PM
Oct-26-21 08:30AM
Sep-30-21 08:30AM
Sep-20-21 08:00AM
Aug-30-21 08:30AM
Aug-24-21 08:30AM
Aug-19-21 09:00AM
08:10AM
Aug-02-21 08:00AM
Jul-29-21 08:00AM
Jul-28-21 08:15AM
Jul-20-21 08:00AM
Jul-12-21 09:51AM
Jul-07-21 08:00AM
Jun-28-21 08:15AM
08:00AM
Jun-10-21 09:12AM
Jun-01-21 08:00AM
May-28-21 08:00AM
May-21-21 04:45PM
Apr-20-21 08:00AM
Apr-19-21 05:00PM
Apr-14-21 08:15AM
Mar-26-21 08:30AM
Mar-25-21 08:30AM
Mar-24-21 08:30AM
Mar-08-21 01:30PM
Feb-24-21 04:00PM
Feb-19-21 09:00AM
Feb-17-21 12:00AM
Jan-11-21 08:00AM
Jan-05-21 02:50PM
Dec-03-20 11:08AM
Nov-24-20 10:00AM
Nov-23-20 08:30AM
180 Life Sciences Corp. operates as a clinical-stage biotechnology company, which engages in the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University. The company was founded by Marc Feldmann, Lawrence J. Steinman, and Jonathan B. Rothbard on September 7, 2016 and is headquartered in Palo Alto, CA.
Last Close
Jul 01 09:36AM ET
0.3990
Dollar change
+0.0030
Percentage change
0.76
%
BCAB BioAtla Inc daily Stock Chart
Index- P/E- EPS (ttm)-1.22 Insider Own23.95% Shs Outstand58.40M Perf Week1.01%
Market Cap23.31M Forward P/E- EPS next Y-1.11 Insider Trans0.00% Shs Float44.43M Perf Month-2.44%
Enterprise Value-8.50M PEG- EPS next Q-0.29 Inst Own18.51% Short Float9.28% Perf Quarter15.05%
Income-61.88M P/S2.12 EPS this Y19.44% Inst Trans-39.52% Short Ratio7.80 Perf Half Y-37.66%
Sales11.00M P/B42.58 EPS next Y4.60% ROA-97.07% Short Interest4.12M Perf YTD-32.51%
Book/sh0.01 P/C0.72 EPS next 5Y8.86% ROE-246.21% 52W High2.53 -84.20% Perf Year-72.86%
Cash/sh0.55 P/FCF- EPS past 3/5Y19.57% -10.97% ROIC-11311.88% 52W Low0.24 66.25% Perf 3Y-88.76%
Dividend Est.- EV/EBITDA- Sales past 3/5Y253.03% 16.17% Gross Margin92.11% Volatility9.23% 12.74% Perf 5Y-
Dividend TTM- EV/Sales-0.77 EPS Y/Y TTM51.11% Oper. Margin-610.00% ATR (14)0.04 Perf 10Y-
Dividend Ex-Date- Quick Ratio2.35 Sales Y/Y TTM- Profit Margin-562.51% RSI (14)46.48 Recom1.67
Dividend Gr. 3/5Y- - Current Ratio2.35 EPS Q/Q45.53% SMA20-7.01% Beta0.90 Target Price5.50
Payout- Debt/Eq1.00 Sales Q/Q- SMA50-7.36% Rel Volume0.23 Prev Close0.40
Employees76 LT Debt/Eq0.00 EarningsMay 06 AMC SMA200-55.82% Avg Volume528.87K Price0.40
IPODec 16, 2020 Option/ShortYes / Yes EPS/Sales Surpr.11.35% - Trades Volume8,008 Change0.76%
Date Action Analyst Rating Change Price Target Change
Nov-13-24Downgrade H.C. Wainwright Buy → Neutral
Sep-15-22Initiated JMP Securities Mkt Outperform $17
May-05-22Downgrade Credit Suisse Outperform → Neutral $35 → $5
Mar-21-22Initiated H.C. Wainwright Buy $25
Oct-15-21Resumed BTIG Research Buy $68
Jun-28-21Initiated ROTH Capital Buy $75
May-05-21Resumed Credit Suisse Outperform $68
Apr-26-21Resumed Credit Suisse Outperform $68
Jan-11-21Initiated JP Morgan Overweight $45
Jan-11-21Initiated Jefferies Buy $51
Jun-02-25 08:00AM
May-07-25 03:21AM
May-06-25 04:05PM
Apr-30-25 08:00AM
Apr-29-25 08:00AM
08:00AM Loading…
Apr-24-25 08:00AM
Apr-23-25 10:05AM
Mar-28-25 12:45PM
03:04AM
Mar-27-25 06:18PM
04:05PM
Mar-20-25 08:00AM
Mar-19-25 08:00AM
Jan-02-25 12:00PM
Dec-20-24 09:00AM
08:00AM Loading…
Dec-16-24 08:00AM
Dec-10-24 08:00AM
08:00AM
Nov-08-24 04:03PM
Nov-07-24 04:01PM
Oct-31-24 08:00AM
Oct-20-24 04:06PM
Oct-09-24 05:57PM
Oct-04-24 09:05AM
Oct-01-24 08:00AM
Sep-23-24 07:30AM
Sep-16-24 08:00AM
Sep-09-24 08:00AM
Aug-28-24 08:00AM
Aug-08-24 04:05PM
08:00AM Loading…
Aug-01-24 08:00AM
Jul-31-24 01:11PM
Jul-25-24 05:39PM
Jul-24-24 12:54PM
Jul-23-24 08:00AM
Jun-27-24 08:00AM
May-29-24 08:00AM
May-23-24 05:05PM
May-15-24 08:18AM
07:01AM
May-14-24 08:57PM
04:05PM
May-08-24 08:00AM
May-07-24 08:00AM
May-06-24 09:14AM
08:00AM
Apr-24-24 04:35PM
Mar-27-24 10:07AM
07:56AM
Mar-26-24 09:54PM
05:33PM
04:01PM
Mar-19-24 08:00AM
Mar-07-24 08:00AM
Dec-20-23 08:00AM
Dec-13-23 08:00AM
Dec-06-23 08:00AM
Dec-05-23 08:00AM
Nov-30-23 08:00AM
Nov-28-23 08:00AM
Nov-12-23 09:24AM
Nov-07-23 04:01PM
Nov-06-23 04:05PM
Oct-12-23 07:30AM
Oct-10-23 07:30AM
Sep-06-23 08:00AM
Aug-03-23 04:01PM
06:48AM
Aug-02-23 11:31AM
Aug-01-23 04:01PM
Jul-25-23 08:00AM
Jul-07-23 07:09AM
Jun-26-23 08:00AM
May-31-23 08:00AM
May-11-23 04:01PM
May-08-23 04:05PM
May-04-23 08:00AM
Apr-29-23 09:29AM
Mar-31-23 06:36AM
Mar-27-23 07:12AM
Mar-24-23 11:31AM
Mar-23-23 04:05PM
Mar-16-23 08:00AM
Feb-27-23 08:07AM
Feb-23-23 08:00AM
Jan-25-23 07:10AM
Jan-10-23 08:00AM
Dec-29-22 04:05PM
Dec-22-22 08:00AM
Dec-08-22 08:54AM
Dec-01-22 09:55AM
Nov-15-22 09:55AM
Nov-11-22 08:38AM
Nov-08-22 08:00AM
Nov-04-22 11:15AM
09:08AM
Nov-03-22 04:01PM
Oct-27-22 08:00AM
Sep-23-22 09:15AM
Sep-21-22 10:14AM
BioAtla, Inc. engages in the development of novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its CAB portfolio include MABs & ADCS, BA3011, and BA3021. The company was founded by Jay M. Short and Carolyn Anderson in March 2007 and is headquartered in San Diego, CA.